How can biomarkers be used in clinical trials in MND?
Related topics
Biomarkers such as neurofilament light chain (NfL) are being used in motor neurone disease (MND) clinical trials to measure biological changes, including neuron damage. The MND Functional Rating Scale-Revised (ALSFRS-R) remains useful for tracking symptoms and daily function. Using both measures can give researchers a fuller picture of how a treatment affects disease progression and people’s lives.
Why this matters
This may help researchers assess treatments more precisely and identify biological effects that are not yet reflected in physical symptoms. However, biomarkers do not show how someone is functioning or how severe their symptoms are, so they do not replace patient-centred measures. This is guidance about trial methods and does not change treatment for people with MND.
Limitations and context
This is an organisational educational blog from the Motor Neurone Disease Association, not a new primary research study. It describes biomarker use and discusses the VALOR trial, but the supplied extract ends during its account of the trial results. Biomarkers still need to be interpreted alongside clinical outcomes, and a change in NfL alone does not establish a treatment benefit.